A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2014
At a glance
- Drugs Ganetespib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Synta Pharmaceuticals
- 18 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jan 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 31 Jan 2014 Planned End Date changed from 1 Jun 2013 to 1 May 2014 as per ClinicalTrials.gov record.